Public Fund Giants Reverse Course With Heavy Hong Kong IPO Cornerstone Allocations Exceeding HK$2.2 Billion Year‑To‑Date

Since the start of 2026, volatility and pullbacks in Hong Kong equities have made new‑issue investing more challenging and pushed the rate of IPOs trading below their offer price toward roughly 40 percent. Against that backdrop, a cohort of large public mutual fund managers has adopted a contrarian stance, acting as cornerstone investors in Hong Kong listings to the tune of more than HK$2.2 billion so far this year, with hard technology, biopharmaceuticals and new‑consumer names rotating through the pipeline. This counter‑cyclical participation has become a notable feature of the primary market in Hong Kong.

Public fund houses and their Hong Kong affiliates have appeared with increasing frequency on cornerstone investor rosters, reversing the caution that prevailed in 2023 and 2024. Wind data show that year‑to‑date commitments by public funds in cornerstone roles have already surpassed HK$2.2 billion. That activity has intensified even as the Hang Seng Index declined more than 3 percent and the Hang Seng Tech Index fell over 24 percent since October 2025, underscoring a clear anti‑cyclical pattern in institutional allocation behavior.

The allocation focus has skewed toward hard technology and advanced manufacturing. Semiconductor issuer Changguang Chenxin, which listed on April 17, counted GF Fund, China Asset Management, E Fund and Fullgoal Fund among its cornerstone backers, with Fullgoal subscribing HK$52.16 million—the largest single public‑fund allocation. Manycore Tech, which listed the same day and is regarded as one of Hangzhou’s notable technology upstarts, secured HK$62.69 million from GF Fund and GF International Asset Management, representing 5.12 percent of the offering. Other recent listings that attracted public fund cornerstone support include Sig Energy in April, Huayan Robotics in March, Han’s CNC in February, and AI and chip companies such as Biren Technology, MiniMax, Zhipu and Tianshu Zhixin in January, which drew commitments from Southern Asset Management, E Fund, GF Fund and China Asset Management (Hong Kong), respectively.

Biopharmaceutical issuers have also featured public funds among their cornerstone investors. Companies such as Rebo Bio, Jingfeng Medical, Jingfang Pharma and Ying’en Bio included China Asset Management, China Asset Management (Hong Kong) and Fullgoal Fund on their cornerstone lists. Notably, several traditional consumer names have received unexpected public‑fund support: snack chain Mingming Henmang, pork producer Muyuan Foods, baby‑diaper maker Leshu Shi and skincare brand Lin Qingxuan all reported public funds among their cornerstone subscribers.

This concentrated wave of cornerstone participation contrasts sharply with the prior two years, when compressed valuations and market uncertainty kept many public funds on the sidelines; Wind records indicate only two public funds acted as cornerstone investors in Hong Kong IPOs across 2023–2024. The current, broader re‑entry reflects a reassessment of Hong Kong’s long‑term allocation value: in a low‑valuation environment, locking in high‑quality assets ahead of recovery has become a shared industry rationale.

Analysts note that public funds are concentrating their cornerstone commitments in three principal sectors—hard technology and advanced manufacturing, biopharma, and new consumption—guided by assessments of corporate fundamentals and sustainable competitive advantages, valuation reasonableness and issuance pricing margins, and the quality of management and governance. The underlying investment logic is straightforward: valuations have moved into historically attractive ranges. As of April 20, the Hang Seng Tech Index’s trailing‑twelve‑month price‑to‑earnings ratio stood at roughly 23 times, near the 35th percentile of its historical distribution, reinforcing the view that parts of the Hong Kong market, particularly technology, are relatively inexpensive.

Market practitioners emphasize that depressed secondary‑market pricing has translated into more conservative IPO pricing, creating entry points for long‑term investors. Some institutions also frame their participation as an arbitrage‑oriented strategy: Hong Kong valuations remain materially lower than comparable A‑share benchmarks, offering a relative‑value opportunity within a defined risk budget. Although the absolute returns from such arbitrage are modest and the risk of post‑listing weakness exists, robust risk management frameworks allow public funds to pursue these allocations as a complement to their relative‑return mandates.

That said, contrarian cornerstone activity carries trade‑offs. The incidence of new Hong Kong listings trading below their offer price has risen in 2026; data through April 20 show a break‑issue rate of 39.53 percent for new listings this year, higher than in 2025. Several recent debuts illustrate the risk: Ulesai Shared plunged 43.64 percent on its first trading day in March, Tongshifu fell 49.17 percent at listing, and even large‑cap names such as Muyuan Foods experienced post‑listing weakness. Observers caution that attractive opportunities are concentrated in a limited set of high‑quality names and that aggregate returns remain sensitive to broader market conditions.

Looking ahead, industry analysts expect the trend of public funds acting as cornerstone investors to persist as more technology leaders pursue Hong Kong listings, but they stress the importance of selective participation. Fund managers will likely place greater emphasis on deep industry research and rigorous stock selection to capture potential excess returns. For retail investors, the consistent advice from institutional participants is to avoid indiscriminate subscription of new issues in a market that is becoming increasingly differentiated; instead, investors should focus on high‑quality companies with sound fundamentals and attractive valuation profiles rather than chasing short‑term momentum.